CSTL - Castle Biosciences Inc. (CSTL) Q1 2024 Earnings Call Transcript
2024-05-04 05:45:21 ET
Castle Biosciences, Inc. (CSTL)
Q1 2024 Earnings Conference Call
May 02, 2024 4:30 PM ET
Company Participants
Camilla Zuckero - VP, IR & Corporate Affairs
Derek Maetzold - President, CEO, Founder & Director
Frank Stokes - CFO
Conference Call Participants
Subbu Nambi - Guggenheim
Kyle Mikson - Canaccord Genuity
Corey Rosenbaum - Scotiabank
Thomas Flaten - Lake Street
Paul Knight - KeyBanc
Mason Carrico - Stephens
Catherine Schulte - Baird
Presentation
Operator
Good afternoon, and welcome to Castle Biosciences First Quarter 2024 Conference Call. As a remainder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question-and-answer session.
I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs. Please go ahead.
Camilla Zuckero
Thank you operator. Good afternoon, everyone. Welcome to Castle Biosciences First Quarter 2024 Financial Results Conference Call. Joining me today is Castle's Founder, President and Chief Executive Officer, Derek Maetzold; and Chief Financial Officer, Frank Stokes. Information recorded on this call speaks only as of today, May 2, 2024. Therefore, if you are listening to the replay or reading the transcript of this call any time-sensitive information may no longer be accurate.
A recording of today's call will be available on the Investor Relations page of the company's website for approximately three weeks following the conclusion of the call. Before we begin, I’d like to remind you that some of the statements made today will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to statements about our financial outlook and similar items referenced in our earnings release issued today and statements containing projections regarding future events or our future financial or operational performance, including our anticipated 2024 total revenue and our 2025 outlook, our expectations regarding reimbursement for our products and the impact of our investments in growth initiatives and expanded commercial team....
Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript